Samsung Biologics Launches Tender Offer for Peptide CDMO PolyPeptide

Samsung Biologics moved a step closer to owning one of the world’s largest independent peptide manufacturers on Monday, when its Swiss subsidiary Samsung Peptide AG published the prospectus for a public tender offer to acquire PolyPeptide Group AG — a CHF 1.46 billion all-cash deal that would fold a six-facility peptide CDMO into the Korean manufacturing giant’s portfolio.

The offer, first pre-announced on July 20, 2026, is a market consolidation story with real consequences for the peptide supply chain: as demand for GLP-1 and other peptide-based drugs rises, a top-tier contract manufacturer is buying its way into the specialist chemistry required to make them at scale.

The Offer Terms

PolyPeptide shareholders are being offered CHF 44.31 net in cash per registered share, which the prospectus values at an implied aggregate equity value of approximately CHF 1.46 billion. That price represents a 40% premium over the unaffected closing price of CHF 31.65 on April 10, 2026 — the last trading day before media speculation about a deal first surfaced — and an 11.6% premium over the volume-weighted average price over the prior 60 trading days.

The PolyPeptide board unanimously recommends that shareholders accept, supported by an independent fairness opinion from IFBC AG. Draupnir Holding B.V., the largest individual shareholder at roughly 55.65% of shares outstanding, has committed to tender its entire position.

The main offer window runs from September 15 to October 12, 2026, subject to a minimum acceptance threshold of 66⅔% on a fully diluted basis and customary regulatory approvals. After settlement, Samsung Peptide intends to squeeze out remaining minority shareholders and delist PolyPeptide from the SIX Swiss Exchange.

Who PolyPeptide Is

PolyPeptide is a specialized contract development and manufacturing organization (CDMO) focused narrowly on peptide-based active pharmaceutical ingredients — the exact chemistry behind GLP-1 receptor agonists and other therapeutic peptides. Dating back to 1952, it operates six GMP-certified facilities across Europe, the U.S., and India, with significant exposure to metabolic diseases including GLP-1.

For Samsung Biologics — already one of the world’s largest CDMOs in antibodies, mRNA, and antibody-drug conjugates — the acquisition adds an entire peptide modality. In its August 28 rights-offering announcement, the company said the deal will “broaden the company’s portfolio into peptide-based therapeutics beyond antibodies and ADCs to better meet rapidly growing global demand for diverse modalities.”

How the Deal Is Funded

The purchase is being financed through a KRW 3 trillion (roughly USD 2.2 billion) rights offering Samsung Biologics announced on August 28. About KRW 2.71 trillion is earmarked for the PolyPeptide acquisition, with the remainder directed to expanding Bio Campus II. The company plans roughly 2.27 million new shares at KRW 1,322,000 each, a discount of about 15% to the reference price.

CEO John Rim framed the raise as a growth bet: “Building on our position as a global top-tier CDMO, this capital raise sets the stage for our next phase of growth. We are confident that executing our three-dimensional growth strategy, including the acquisition of PolyPeptide Group and the expansion of Bio Campus II, will deepen our leadership and create lasting value for shareholders.”

The market response was cooler. Bloomberg reported that Samsung Biologics shares fell as much as 7.2% on the Friday after the announcement, a sign investors are weighing the dilutive cost of the raise against the strategic prize.

What It Means for the Peptide Supply Chain

The deal lands at a moment when peptide manufacturing capacity is under unusual scrutiny. In July, the FDA’s Pharmacy Compounding Advisory Committee narrowly backed broader compounding access for several unapproved peptides — a decision PeptidesBeat covered in detail — that could expand demand for exactly the kind of peptide API production PolyPeptide provides.

It is also the latest in a string of peptide-focused manufacturing and licensing moves. Vector Science announced new peptide production capacity in late August, and Roche and Hanmi inked an obesity-peptide deal in the same window. Samsung’s acquisition of PolyPeptide is the largest of them — and the clearest signal yet that established CDMOs expect peptide chemistry, not just biologics, to drive the next phase of the market.

The tender offer remains subject to regulatory approval and the 66⅔% acceptance condition. If it clears, PolyPeptide’s peptide capacity becomes part of a manufacturer with 1,385,000 liters of planned global capacity by 2032 — and the peptide supply chain gets a more concentrated owner.

Disclaimer: This article is for informational purposes only and is not financial or investment advice. PeptidesBeat does not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question and a qualified financial professional for any investment decision.